Core Insights - JD Health and Homart Group announced a deepened collaboration to develop new products tailored to Chinese consumers' needs, aiming to enhance the standardization, transparency, and scientific development of the nutrition and health industry in China [1][2] Group 1: Collaboration Details - The partnership will leverage JD Health's consumer insights and big data for precise product recommendations and content delivery, utilizing diverse formats like live streaming and short videos to connect emotionally with consumers [1] - Integrated services will be provided, including online consultations with doctors and nutritionists, creating a comprehensive "product + service" solution for consumers [1] - JD's advanced logistics system will ensure efficient and safe delivery of Homart's products nationwide, significantly improving the health consumption experience [1] Group 2: Company Background - Homart Group, a well-established Australian health company with 33 years of history, adheres to the philosophy of "global selection, natural health" and operates under strict Australian cGMP certification and TGA standards [2] - The flagship brand, SpringLeaf, focuses on combining natural ingredients with modern technology to offer safe and effective health support [2] - Homart has been actively promoting China-Australia cooperation and has participated in the China International Import Expo (CIIE) for seven consecutive years, receiving the "Best Achievement of CIIE" award in 2025 [2] Group 3: Future Outlook - JD Health aims to leverage its capabilities as a "global health new product online launch platform" to integrate international quality resources and collaborate with brands like Homart, driving the Chinese nutrition and health consumption market towards a more professional and user-centric phase [2]

Core Insights - JD Health and Noromega have announced a deep cooperation to launch Noromega's annual million-unit premium seal oil product on JD Health's global health new product online debut platform, aiming to enhance the marine health food quality ecosystem and promote the dietary nutrition industry towards refinement and specialization [1][2]. Group 1: Company Collaboration - JD Health has chosen to collaborate with Noromega due to its outstanding product quality and control capabilities in the marine nutrition category [2]. - Noromega's seal oil is sourced from high-quality raw materials in the pristine waters of the Arctic Circle and has received ORIVO 100% pure seal oil certification, setting a new quality benchmark in the marine nutrition category [2]. Group 2: Product Launch and Market Strategy - The collaboration marks the launch of the premium seal oil series, which reflects Noromega's commitment to enhancing product quality standards, particularly in core categories like seal oil [2]. - JD Health plans to continue partnering with global nutrition brands like Noromega to ensure the precise introduction and sustained growth of global nutrition new products in the Chinese market, providing consumers with scientific, safe, and effective health products and nutritional solutions [2].

Core Viewpoint - Southbound funds have increased their holdings in JD Health (06618.HK) by 605,600 shares on November 6, indicating a growing interest from investors in the company [1]. Group 1: Shareholding Changes - In the last 5 trading days, JD Health has seen an increase in holdings for 3 days, with a total net increase of 407,300 shares [1]. - Over the past 20 trading days, there have been 14 days of net increases, totaling 3,119,900 shares [1]. - As of now, southbound funds hold 279 million shares of JD Health, accounting for 8.72% of the company's total issued ordinary shares [1]. Group 2: Trading Data - On November 6, 2025, the total shareholding was 279 million, with a change of 605,600 shares, reflecting a 0.22% increase [2]. - On November 5, 2025, the total shareholding remained at 279 million, with a change of 409,400 shares, a 0.15% increase [2]. - On November 4, 2025, the total shareholding was 278 million, with a decrease of 210,300 shares, a -0.08% change [2]. - On November 3, 2025, the total shareholding was 279 million, with an increase of 331,100 shares, a 0.12% change [2]. - On October 31, 2025, the total shareholding was 278 million, with a decrease of 728,400 shares, a -0.26% change [2]. Group 3: Company Overview - JD Health is primarily engaged in providing pharmaceutical and health products, internet medical health services, health management, and intelligent medical health solutions [2]. - The company's business includes retail pharmacy and medical health services, with retail pharmacy operations conducted through self-operated and online platforms as well as instant retail channels [2]. - Medical health services are mainly provided through internet hospitals and medical models, along with online marketing services such as advertising [2].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 京东健康股份有限公司 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06618 | | 說明 | | | | | | | | | 多櫃檯證券代號 | 86618 | RMB | 說明 | | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | | 100,000,000,000 | USD | | 0.0000005 | USD | | 50,000 | | 增加 / 減少 (-) | | | | 0 | | | | USD | | 0 | | 本月底結 ...

Core Viewpoint - Southbound funds increased their holdings in JD Health (06618.HK) by 409,400 shares on November 5, 2025, indicating a positive sentiment towards the company [1]. Group 1: Shareholding Changes - In the last five trading days, there were two days of net reductions in holdings by southbound funds, totaling a net decrease of 137,200 shares [1]. - Over the past twenty trading days, southbound funds increased their holdings on fourteen occasions, resulting in a cumulative net increase of 2,579,100 shares [1]. - As of now, southbound funds hold 279 million shares of JD Health, accounting for 8.7% of the company's total issued ordinary shares [1]. Group 2: Company Overview - JD Health is primarily engaged in providing pharmaceutical and health products, internet medical health services, health management, and intelligent medical health solutions [2]. - The company's business includes retail pharmacy operations, which sell pharmaceutical and health products as well as medical devices through self-operated and online platforms, as well as instant retail channels [2]. - JD Health also offers medical health services through internet hospitals and medical models, along with online marketing services such as advertising [2].

Core Points - The article highlights the importance of flu prevention, especially for the elderly, and discusses a donation initiative by JD Health to support rural elderly populations in China [1] Group 1: Company Initiatives - JD Health, in collaboration with the China Social Relief Foundation, is donating a batch of small medicine boxes and flu prevention medications to 50 village health clinics in cities like Hebi and Xinxiang in Henan Province, benefiting over 20,000 rural elderly individuals [1] - The initiative aims to provide better access to medication and health services for elderly individuals in rural areas, where healthcare resources are limited [1] Group 2: Industry Context - The article notes that the elderly are particularly susceptible to flu, which can lead to severe complications such as pneumonia and myocarditis, making preventive measures crucial [1] - There is a significant increase in the demand for flu-related medications, with JD Health reporting a notable rise in search volumes for drugs like Oseltamivir, Mabalasavir, and 999 Cold Medicine Granules during the autumn and winter seasons [1]

Core Insights - JD Health and Innovent Biologics have signed a strategic cooperation agreement, focusing on weight management and showcasing their collaborative achievements in the industry [1] - Innovent Biologics has 16 commercialized products and aims to advance approximately 10 new molecular entities into clinical trials each year [1] - The recently approved drug, Ma Shidu Tai (信尔美), is the world's first GLP-1 and GCG dual-target drug, demonstrating significant advantages in weight loss and blood sugar reduction [1] Group 1: Company Collaboration - JD Health leverages its "super supply chain" advantage to provide a new model for the biopharmaceutical industry [1] - The partnership aims to create a complete ecosystem from drug research and development to production, distribution, and service [3] Group 2: Market Trends and Consumer Behavior - JD Health has developed a one-stop service for chronic disease management, allowing users to access healthcare services from home [2] - The online channel has become a significant entry point for weight management, with over a million users searching for "Ma Shidu Tai" within a month of its launch [2] - There is a notable shift in consumer demographics for GLP-1 drugs, with a high proportion of users from lower-tier cities, indicating improved accessibility through online channels [2] Group 3: Industry Implications - The national strategy for weight management highlights the importance of addressing obesity as a root cause of chronic diseases [3] - The collaboration between JD Health and Innovent Biologics is redefining the service model for weight management in China, aligning with the mission to make high-quality biopharmaceuticals affordable for the public [3]

Core Insights - The forum focused on "technology empowering the assistive care industry," discussing innovations in smart rehabilitation devices, digital health services, and AI technology in the assistive care sector [1][2] - There is a growing demand for high-quality medical health products and services among the disabled population, with significant increases in search volumes for assistive devices since 2025 [1][2] - JD Health's assistive care supply now covers over 30,000 brands and thousands of subcategories, addressing the full spectrum of health needs for disabled individuals [2] Group 1 - The 17th Health China Forum, supported by JD Health, highlighted the importance of technology in enhancing the quality of life for disabled individuals [1] - JD Health's "Assistive Care Zone" launched in May, featuring three main sections: assistive devices, labor products for the disabled, and intelligent health services [2] - The company aims to solve the "last mile" care challenge by providing a comprehensive service loop that includes online consultations, home testing, and medication delivery [2] Group 2 - AI technology is a core competitive advantage for JD Health, leveraging its proprietary medical model and extensive user health data [2] - JD Health has established the largest medical device knowledge base in the industry, with over 1.5 billion user health records [2] - The company plans to deepen its "product + service + AI" innovation model and collaborate with more industry partners to create a smarter and more efficient assistive care ecosystem [3]

Core Insights - JD Health is showcasing its strengths in the pet healthcare sector at the 2025 Upet Pet Life Expo in Beijing, emphasizing its comprehensive supply chain and hospital services for pet medications [1] - The establishment of the "JD Pet Health Good Pet Medicine Alliance" aims to enhance product reliability and service quality for users [1] Supply Chain and Product Offerings - JD Health has built the most comprehensive online pet medication supply chain, covering 132 types of pet medication, including deworming, prescription drugs, and skin care products [2] - The company achieved a significant milestone by offering compliant pet vaccines online, supported by a complete cold chain system and professional after-sales service [2] Sales Growth and Market Position - JD Health's pet medication sales growth significantly outpaces the industry average, with a 3.6 times increase in prescription food sales and over 90% growth in specialized treatment medications in 2024 [2] - The pet hospital services have become the largest and most innovative online pet hospital in the industry, with over 5,500 licensed veterinarians and partnerships with more than 2,400 offline animal hospitals [2] Brand Collaboration and Future Plans - JD Health is enhancing brand collaboration through initiatives like "Love Pets Together Day," partnering with over 20 brands to drive valuable growth [3] - The company plans to improve user pet profile systems and launch 28 new pet health products in 2025, including notable products from leading pharmaceutical companies [3] - JD Health aims to provide a comprehensive, professional, and convenient one-stop pet health solution by strengthening its supply chain and collaborating with more brand partners [3]

Core Insights - JD Health is positioning itself as a leading new medical health service provider in the pet health sector, showcasing its strengths in the pet medicine supply chain and hospital services at the 2025 Upet Pet Life Expo in Beijing [1][3] - The establishment of the "JD Pet Health Good Medicine Alliance" aims to unite industry forces to provide users with more reliable products and services [1] Company Developments - JD Health has completed a comprehensive layout of "medical, testing, medicine, and insurance" in its pet health business, reinforcing its position as a trusted pet health service platform [3] - The company has built the most comprehensive online pet medicine supply chain in the industry, covering 132 pet medicine product approvals, including core categories such as deworming, prescription drugs, and skin care [4] - JD Health's pet medicine sales growth significantly outpaces the industry average, with a 3.6 times increase in prescription food transaction value and over 90% growth in specialized treatment medication sales in 2024 [4] Service Capabilities - JD Health's pet hospital has become the largest and most professional online pet hospital in the industry, with over 5,500 licensed veterinarians and partnerships with over 2,400 offline animal hospitals [5] - The platform offers 24/7 online consultation services, with an average response time of 8 seconds, serving 4.2 million pet owners and achieving a 99.5% order satisfaction rate [5][6] - The use of AI technology in the form of the "JD Medical Inquiry" model allows for automatic responses to 54% of common inquiries, saving pet owners over 6 million in consultation fees annually [6] Ecosystem Development - JD Health is enhancing brand collaboration by leveraging its marketing capabilities, having partnered with over 20 brands to create the "Love Pet Long Companion Day" IP [7] - In 2025, 28 new pet health products will be launched on JD Health's platform, with significant sales achievements already noted for some products [7] - The company aims to build a robust pet health product supply chain and improve its full-cycle service capabilities in collaboration with more brand partners [12] Industry Trends - Industry representatives discussed trends in preventive care, nutrition management, and service experience, emphasizing the need for continuous innovation and quality in pet medicine [9][10] - The online consultation trend is seen as a solution to urgent user needs, breaking spatial and temporal limitations [10]